This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Anyone quoting an eligibility threshold should cite the national document, because thresholds differ between states and have changed within them.
The short version is the first sentence; the rest is why.
Worth stating the null on cross-border purchase rules within before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Post #29 and I disagree about the size of the effect, not about the direction.
The public assessment report published at authorisation is one of the best free technical documents available on any of these compounds and it is rarely cited here.
A partial answer, offered because a partial answer beats none.
Taking post #33 at face value and following it one step further.
The arithmetic on cross-border purchase rules within is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
Coming back to post #33, because the follow-up matters more than the original answer.
I read the earlier replies on cross-border purchase rules within twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Adding a data point of agreement rather than a data point.
This follows post #37 rather than contradicting it.
Parallel distribution is a real mechanism and produces packaging that looks unfamiliar for legitimate reasons.
It cost nothing to check and would have cost something not to.
Answering the question post #37 raises rather than the one it answers.
Members outside the union should note that essentially none of this transfers, including the parts phrased generally.
The arithmetic in post #37 is right; the assumption feeding it is the part to check.
I have three months of notes on cross-border purchase rules within and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Everything in post #40 holds. The case it does not cover is the one I have.
Movement of medicines between member states for personal use has rules, and they are published rather than a matter of custom.
Building on post #42 rather than restating it.
Small correction to my own earlier position on cross-border purchase rules within. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
Noted, and I have changed what I was going to do on the strength of it.
The arithmetic in post #42 is right; the assumption feeding it is the part to check.
I would put moderate confidence on the mainstream reading of cross-border purchase rules within and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
My experience of cross-border purchase rules within contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
Adding the measurement that post #46 says would settle it.
What I would want before treating cross-border purchase rules within as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. A methods question rather than a substantive one, about eu-wide position versus national…
|
2 | 54k | 19mo | |
|
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Something about EMA product information does not reconcile and I would like a…
|
+70 | 74 | 7k | 8mo |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Something about EMA product information does…
|
+127 | 150 | 41k | 20mo |
|
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. I have spent a fortnight trying to pin German down and I want…
|
+90 | 99 | 32k | 9mo |
|
About the European Union category
EMA positions, national differences within the EU, and cross-border purchase rules. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+1 | 5 | 18k | 10mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. Cross-border purchase rules within — I have the observation and I do not trust my…
|
+12 | 16 | 2.8k | 11mo |
|
Prior authorisation: what the criteria usually require
On the subject in the title: Prior authorisation: what the criteria usually require Working notes rather than a conclusion. I would like to know what people here actually do about prior authorisation, as…
|
+9 | 13 | 3.2k | 17mo |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
|
+87 | 94 | 1.1k | 21d |
|
[2026 update] Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+40 | 45 | 14k | 4mo |
|
What changed in 2026, by region
What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…
|
+110 | 122 | 1.4k | 18mo |